Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,363
Recruiting: 3,965
Ph III recruiting: 535
Growth YoY: +10.3%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,404)

clinicaltrialsPublishedShowing 3,801–3,850 of 3,853 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05548504	Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC(HERAN2)	not yet recruiting	Phase 2	182	Odense University HospitalOTHER	0	Sep 21, 2022	clinicaltrials
NCT05190445	Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma	active not recruiting	Phase 2	80	Pieris Pharmaceuticals, Inc.INDUSTRY	2